Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer. – Brinkwire
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
General21 hours agoSearch underway for missing boat off South Australia’s Cape Jaffa
-
Noosa News22 hours agoQueensland coroner investigates ‘extremely unusual’ deaths of premature twin boys
-
Noosa News23 hours agoChristmas tragedy: NSW woman dies after alleged deliberate hit-and-run on Sunshine Coast
-
Noosa News8 hours agoThe Best Things to Do in Brisbane This New Year’s Eve